Skip Navigation

JNCI Monographs 2004 2004(33):134-141; doi:10.1093/jncimonographs/lgh018
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fryback, D. G.
Right arrow Articles by Craig, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fryback, D. G.
Right arrow Articles by Craig, B. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

2004 © Oxford University Press

Article

Measuring Economic Outcomes of Cancer

Dennis G. Fryback, Benjamin M. Craig

Dennis G. Fryback, Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI; Benjamin M. Craig, Department of Pharmacy, Practice, and Science, College of Pharmacy, University of Arizona, Tucson, AZ.

Correspondence to: Dennis G. Fryback, PhD, Department of Population Health Sciences, University of Wisconsin-Madison, 610 N. Walnut Street, Room 685, Madison, WI 53726 (e-mail: dfryback{at}wisc.edu).

Economic outcomes are increasingly important in cancer research. This article provides an introduction to the nature and measurement of economic outcomes in cancer and gives the reader entry points to a considerable literature on measuring economic endpoints in health and medicine. Economic outcomes data are defined here as measures of resources consumed in prevention, detection, and treatment of cancer and its sequellae. Part I of this essay discusses the questions addressed by economic outcomes. Part II presents a typology of and introduction to measurement of economic outcomes. Part III discusses important measurement issues and calls for development and validation of standardized protocols and questionnaires to measure economic outcomes, especially at the patient level.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JRSMHome page
R. MacKenzie, S. Chapman, G. Salkeld, and S. Holding
Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
J R Soc Med, June 1, 2008; 101(6): 305 - 312.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. B. Schechter
Cost Effectiveness in Context
J. Clin. Oncol., February 20, 2007; 25(6): 609 - 610.
[Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
J. Lipscomb, M. S. Donaldson, and R. A. Hiatt
Cancer Outcomes Research and the Arenas of Application
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 1 - 7.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.